Autologous CD34+ cells hold promise to prevent tissue damage and restore blood flow in diabetic individuals or individuals with metabolic syndrome who may not be ideal candidates for standard revascularization procedures due to a diffuse vascular disease or failed previous revascularization. Here, CD34 is linked to metabolic syndrome.